PerkinElmer, Inc. has announced the launch of the new LabChip® GX Touch and GXII Touch™ automated electrophoresis systems.
The LabChip platform’s key feature is automation of conventional gel electrophoresis, eliminating the need for manual sample preparation.
The LabChip GX Touch and GXII Touch benefit customers by reducing hands-on time and simplifying data generation via a user friendly operator touch screen.
The LabChip platform provides the data and throughput necessary to perform effective nucleic acid quantification and protein characterization. The LabChip GX system can enhance genomics research process by precisely quantifying nucleic acids. The GXII Touch system helps to accelerate the development of biotherapeutic drugs by automating the protein characterization process.
“We launched the LabChip platform to provide enhanced workflows for genomics research as well as to speed up the discovery of breakthrough biotherapeutic drugs,” said Brian Kim, President, Life Sciences & Technology, PerkinElmer. “With these two new systems, scientists can harness microfluidics capabilities to obtain results more quickly and efficiently, improve their processes, and make significant research advancements.”
Current Quality by Design (QbD) initiatives underscore the need to identify and understand critical quality attributes, which are features of a therapeutic protein that affect its efficacy. Tight monitoring and control of these attributes helps to ensure stable, more predictable pharmacological response.
The LabChip GXII Touch system’s rapid reporting of multiple protein critical quality attributes can support customer needs throughout the product life cycle.
The LabChip Touch platform’s top differentiator is its ability to perform electrophoresis in microfluidic channels. The LabChip GX Touch system provides rapid, quantifiable data for pre and post-PCR sample analysis, which is critical for next-generation sequencing and genomics workflows.
The LabChip GXII Touch system quantifies protein attributes from process development through quality control in biotherapeutics development and manufacturing.